Logo

American Heart Association

  8
  0


Final ID: Sa1116

VTRNA2-1 Promoter Methylation as a Prognostic Biomarker in Peripheral Artery Disease: Implications for Maternal Nutritional Influence

Abstract Body (Do not enter title and authors here): Background
Peripheral artery disease (PAD) is associated with high morbidity and mortality and is closely related to diabetes mellitus (DM) and atherosclerosis. Recent advances in epigenetics have highlighted the critical relationships of non-coding RNA Vault RNA 2-1 (VTRNA2-1) promoter methylation and periconceptional nutritional status. Furthermore, the abundance of methylation of the VTRNA2-1 promoter is associated with glucose metabolism and cell aging. This study investigates the association between VTRNA2-1 promoter methylation and clinical outcomes in PAD patients requiring revascularization.
Hypothesis
VTRNA2-1 promoter methylation status is associated with clinical outcomes in PAD patients requiring revascularization.
Methods
A total of 133 PAD patients requiring revascularization were enrolled. Inclusion criteria included adults over 20 years old, consent to participate, and a requirement for angioplasty. Blood samples were processed to isolate leukocytes, and DNA was extracted using the DNeasy blood kit. Bisulfite pyrosequencing was performed to quantify CpG site-specific DNA methylation at the VTRNA2-1 promoter locus. General population samples from the National Health Research Institutes were used as the control group to compare the methylation status. Patients' one-year clinical outcomes were evaluated.
Results
The study found significant differences in VTRNA2-1 promoter methylation status between PAD patients and the control group (P < 0.001). Hypomethylation of VTRNA2-1 promoter was associated with a higher amputation rate in PAD patients (HR 2.19, 95% CI 1.09-4.42, p=0.027). Among patients without ESRD (N=79), those with hypomethylation had a significantly increased risk of major adverse limb events (MALE) (HR 2.78, 95% CI 1.11-6.97, p=0.024), amputations (HR 2.58, 95% CI 1.02-6.57, p=0.044), and progression to ESRD (p=0.039).
Conclusion
The methylation status of VTRNA2-1 promoter is significantly different between PAD patients and the normal population, with hypomethylation linked to poorer clinical outcomes in PAD patients undergoing revascularization. These findings suggest that VTRNA2-1 promoter methylation status could serve as a valuable biomarker for predicting prognosis and guiding treatment strategies in PAD. Our results open a molecular link between the periconceptional environment and the risks of PAD.
  • Tsai, Ming-lung  ( Municipal TuCheng Hospital , New Taipei City , Taiwan )
  • Huang, Yi-chun  ( Chang Gung Memorial Hospital (Linkou Branch) , Taoyuan , Taiwan )
  • Wang, Chao-yung  ( Chang Gung Memorial Hospital (Linkou Branch) , Taoyuan , Taiwan )
  • Author Disclosures:
    Ming-lung Tsai: DO NOT have relevant financial relationships | Yi-Chun Huang: DO NOT have relevant financial relationships | Chao-Yung Wang: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

From Lungs to Toes, WAZE Around Peripheral Clots and Blocks

Saturday, 11/16/2024 , 02:00PM - 03:00PM

Abstract Poster Session

More abstracts on this topic:
Artificial Intelligence-Enhanced Electrocardiogram Trajectories for Age Estimation: Prognostic Assessment and Differential Prediction of Atrial Fibrillation Occurrence

Hwang Taehyun, Pak Hui-nam, Lee Moon-hyoung, Yu Hee Tae, Joung Boyoung, You Seng Chan, Kim Sangyeol, Eom Sujeong, Boo Dachung, Kim Subin, Kim Daehoon, Kim Tae-hoon, Uhm Jae-sun

Burden of coronary artery disease predicts mortality in ischaemic stroke patients: The Norwegian Stroke in the Young Study

Jibril Khuluud Abdi, Saeed Sahrai, Nawaz Beenish, Waje-andreassen Ulrike, Naess Halvor, Fromm Annette, Ali Abukar, Larsen Terje Hjalmar, Bleie Oyvind, Kuiper Kier Jan

You have to be authorized to contact abstract author. Please, Login
Not Available